Individual and combination of mdvi-1 and nutlin-3 for topical or intravitreal ophthalmic use

ABSTRACT

Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.

RELATED APPLICATION

This application is a Divisional application of U.S. Ser. No.12/715,384, filed Mar. 2, 2010. The disclosure of which is incorporatedherein by reference.

BACKGROUND OF THE INVENTION

This invention relates to the topical and/or intravitreal ophthalmic useof mdivi-1 and nutlin-3, individually or in combination, when indicatedfor treatment of glaucoma, ischemic optic neuropathies, hereditary opticneuropathies and retinal artery and vein occlusions.

Nutlin-3 is disclosed in U.S. Pat. Nos. 6,617,346, 6,734,302, 6,916,833,7,060,713, 7,425,638, 7,579,368, 7,625,895. The claims of the listedpatents describe nutlin-3 inhibition of the interaction of MDM2 proteinwith a p53-like peptide and hence have anti proliferative activity. Inthis invention, nutlin-3 inhibit apoptosis by inhibiting Bax and Bak inthe apoptosis pathway and produce neuroprotective effects rather thaninduce apoptosis as claimed in the previous patent disclosures.

mdivi-1 is disclosed in U.S. Pat. Application No. 20050038051 and20080287473. The claims of the listed patents describe mdivi-1regulation of apoptosis via regulating mitochondrial fission or fusion.

This patent claims nutlin-3 and mdivi-1 as an ophthalmic drug. Incombination, these drugs block Bax/Bak and Drp1 interaction on themitochondria surface as a key step in the apoptotic pathway of variousophthalmic diseases including glaucoma, ischemic optic neuropathy,hereditary optic neuropathy and retinal artery/vein occlusions.

DESCRIPTION

Nutlin-3 is represented by the chemical formulae (I) and (II) depictedbelow described in U.S. Pat. Nos. 6,617,346, 6,734,302, 6,916,833,7,060,713, 7,425,638, 7,579,368, 7,625,895.

wherein R is —C═OR₁,wherein R₁ is C1-C4 alkyl, —C═CHCOOH, —NHCH₂CH₂R₂, —N(CH₂CH₂OH)CH₂CH₂OH,—N(CH₃)CH₂CH₂NCH₃, —N(CH₃)CH₂CH₂N(CH₃)CH₃, saturated 4-, 5- and6-membered rings, saturated and unsaturated 5- and 6-membered ringscontaining at least one hetero atom wherein the hetero atom is selectedfrom S, N and O and being optionally substituted with a group selectedfrom lower alkyl, —C═O—R₅, —OH, lower alkyl substituted with hydroxy,lower alkyl substituted with —NH₂, N-lower alkyl, —SO₂CH₃, ═O,—CH₂C═OCH₃, and 5- and 6-membered saturated rings containing at leastone hetero atom selected from S, N and O,wherein R₅ is selected from H, lower alkyl, —NH₂, —N-lower alkyl, loweralkyl substituted with hydroxy, and lower alkyl substituted with NH₂,wherein R₂ is selected from —N(CH₃)CH₃, —NHCH₂CH₂NH₂, —NH₂, morpholinyland piperazinyl,X₁, X₂ and X₃ are independently selected from —OH, C1-C2 alkyl, C1-C5alkoxy, —Cl, —Br, —F, —CH₂OCH₃, and —CH₂OCH₂CH₃, or one of X₁, X₂ or X₃is H and the other two are independently selected from hydroxy, loweralkyl, lower alkoxy, Cl, Br, F, CF₃—CH₂OCH₃, —CH₂OCH₂CH₃—OCH₂CH₂R₃,—OCH₂CF₃, and —O—R₄,or one of X₁, X₂ or X₃ is H and the other two taken together with thetwo carbon atoms and the bonds between them from the benzene ring towhich they are substituted form a 6-membered saturated ring thatcontains at least one hetero atom selected from S, N, and O,wherein R₃ is selected from —F, —OCH₃, —N(CH₃)CH₃, unsaturated5-membered rings containing at least one hetero atom wherein the heteroatom is selected from S, N and O,wherein R₄ is a 3- to 5-membered saturated ring andY₁ and Y₂ are each independently selected from —Cl, —Br, —NO₂, —C≡N and—C≡CH.

wherein R is —C═OR₁,wherein R₁ is selected from C1-C4 alkyl, saturated 5- and 6-memberedrings, saturated 5- and 6-membered rings containing at least one heteroatom wherein the hetero atom is selected from S, N and O and beingoptionally substituted with a group selected from C1-C2 alkyl, C1-C3alcohol, —N(CH₃)CH₃, and —C═OCH₃, and 5- and 6-membered rings containingat least one hetero atom wherein the hetero atom is selected from S, N,and O,X₄ is selected from C1-C2 alkyl, C1-C5 alkoxy, —Cl, —Br, —F, —OCH₂C=OOQ,—OCH₂ cyclopentyl, —CH₂OCH₂-phenyl, saturated and unsaturated 5- and6-membered rings, saturated and unsaturated 5- and 6-membered ringscontaining at least one hetero atom wherein the hetero atom is selectedfrom S, N and O,wherein Q is selected from H and lower alkyl,Y₁ and Y₂ are independently selected from —Cl, —Br, —NO₂, —C≡N and—C≡CH,with the proviso that where Y₁ and Y₂ are both —Cl, and R₁ is —CH₃ orphenyl, then X₄ is not —Cl.

Mdivi-1 is represented by the chemical formula (III) depicted belowdescribed in U.S. Pat. Application No. 20050038051 and 20080287473.

wherein R₁ is independently H; a C1-C18 alkyl, which may be branched,may contain a heteroatom or may be substituted, or combinations thereof;a C1-C18 alkenyl, which may be branched, may contain a heteroatom or maybe substituted, or combinations thereof; a C1-C18 alkynl, which may bebranched, may contain a heteroatom or may be substituted, orcombinations thereof; a C3-C18 aryl which may contain a side group, maycontain a bridge, may contain a heteroatom or may be substituted, orcombinations thereof; or a C5-C18 cycloalkyl which may contain a sidegroup, may contain a bridge, may contain a heteroatom or may besubstituted, or combinations thereof;R₂ is H; a C1-C18 alkyl, which may be branched, may contain a heteroatomor may be substituted, or combinations thereof; or a halogen;R₃ is H; a C1-C18 alkyl, which may be branched, may contain a heteroatomor may be substituted, or combinations thereof;R₄ is H or a halogen; andR₅ is H or a halogen,with the provisos that when R₃ is H and R₄ is H or a halogen, R₅ is ahalogen, or when R₂ is a halogen R₅ is H or a halogen.

Nutlin-3 and its active emantiomer nutlin-3a are available from Roche,Inc and Cayman Chemical, Inc. Mdivi-1 is available from various sources,including Enzo Life Science.

The compositions of the present invention are administered eithertopically or intravitreally. The dosage is 0.001 to 1.0, e.g. mg/per eyeBID to QID or as 1 time dose; wherein the cited mass FIGURES representthe sum of the two components, mdivi-1 and nutlin-3. The compositions ofthe present invention can be administered as solutions in a suitableophthalmic vehicle.

The precise regimen is left to the discretion of the clinician, it isrecommended that the solution be topically applied by placing one dropin each eye once to four times a day or as one time or weeklyintravitreal injections. Other ingredients which may be desirable to usein the ophthalmic preparations of the present invention includepreservatives, co-solvents and viscosity building agents.

Antimicrobial Preservative

Ophthalmic products are typically packaged in multidose form.Preservatives are thus required to prevent microbial contaminationduring use. Suitable preservatives include: benzalkonium chloride,thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethylalcohol, edetate disodium, sorbic acid, Onamer M, or other agents knownto those skilled in the art. In the prior art ophthalmic products,typically such preservatives are employed at a level of from 0.004% to0.02%. In the compositions of the present application the preservative,preferably benzalkonium chloride, may be employed at a level of from0.001% to less than 0.01%, e.g. from 0.001% to 0.008%, preferably about0.005% by weight. It has been found that a concentration of benzalkoniumchloride of 0.005% is sufficient to preserve the compositions of thepresent invention from microbial attack. This concentration may beadvantageously compared to the requirement of 0.01% benzalkoniumchloride to preserve mdivi-1 and nutlin-3 in the individual,commercially—available ophthalmic products. It is noted that it is knownthat benzalkonium chloride at high concentrations is cytotoxic.Therefore, minimizing the patient's exposure to benzalkonium chloride,while providing the preservative effects afforded by benzalkoniumchloride, is clearly desirable.

Co-Solvents

The solubility of the components of the present compositions may beenhanced by a surfactant or other appropriate co-solvent in thecomposition. Such cosolvents include polysorbate 20, 60, and 80,Pluronic F68, F-84 and P-103, cyclodextrin, or other agents known tothose skilled in the art. Typically such co-solvents are employed at alevel of from 0.01% to 2% by weight.

Viscosity Agents

Viscosity increased above that of simple aqueous solutions may bedesirable to increase ocular absorption of the active compound, todecrease variability in dispensing the formulation, to decrease physicalseparation of components of a suspension or emulsion of the formulationand/or to otherwise improve the ophthalmic formulation. Such viscositybuilding agents include as examples polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxy propyl methylcellulose,hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propylcellulose or other agents known to those skilled in the art. Such agentsare typically employed at a level of from 0.01% to 2% by weight.

The present invention further comprises an article of manufacturecomprising packaging material and a pharmaceutical agent containedwithin said packaging material, wherein the pharmaceutical agent istherapeutically effective for neuroprotection and wherein the packagingmaterial comprises a label which indicates the pharmaceutical agent canbe used for lowering intraocular pressure and wherein saidpharmaceutical agent comprises an effective amount of mdivi-1 and aneffective amount of nutlin-3.

The following example is a representative pharmaceutical composition ofthe invention for topical use when indicated for treating glaucoma,ischemic optic neuropathy, hereditary optic neuropathy and retinalartery or vein occlusion.

Example I

The combination of active pharmaceutical ingredients is as follows:mdivi-1 0.10% (w/v) and nutlin-3 Maleate 0.25% (w/v).

The formulation vehicle contains an isotonic phosphate buffer system atpH 6.9. The formulation preservative is benzalalkonium chloride (BAK) ata concentration of 0.005% (w/v) (50 ppm).

The invention has been described herein by reference to certainpreferred embodiments. However, as obvious variations thereon willbecome apparent to those skilled in the art, the invention is not to beconsidered as limited thereto.

A1. A method of treating glaucoma, ischemic optic neuropathy or retinalartery or vein occlusion by topical or intravitreal administration ofnutlin-3, including the active enantiomer nutlin-3a, to an eye of aperson in need once to four times a day or as one time or weeklyintravitreal injections as the sole active agent.

A2. A method of treating glaucoma, ischemic optic neuropathy or retinalartery or vein occlusion by topical or intravitreal administration ofmdivi-1 to an eye of a person in need once to four times a day or as onetime or weekly intravitreal injections as the sole active agent.

A3. A method of treating glaucoma, ischemic optic neuropathy or retinalartery or vein occlusion by topical administration of nutlin-3(including the active enantiomer nutlin-3a) to an eye of a person inneed thereof, said improvement comprising topically administering tosaid eye, in a single composition, nutlin-3 and mdivi-1 once to fourtimes a day topically or as one time or weekly intravitreal injections;as the sole active agents; wherein said method is as effective asadministration of nutlin-3 once to four times a day and mdivi-1 once tofour times a day or as one time or weekly intravitreal injections tosaid eye, herein the two compounds are administered in separatecompositions.

What is claimed is:
 1. A method of treating ischemic optic neuropathy inan eye of a person in need thereof, the method comprising administering,to the person, a composition comprising a therapeutically effectiveamount of mdivi-1.
 2. The method of claim 1, wherein the composition isadministered to said person once to four times per day.
 3. The method ofclaim 1, wherein the composition is administered once per week.
 4. Themethod of claim 1, wherein the composition is administered once.
 5. Themethod of claim 1, wherein the composition is formulated forintravitreal injection or topical delivery.
 6. The method of claim 5,wherein the composition is formulated for intravitreal injection.
 7. Themethod of claim 1, wherein the composition further comprises apreservative.
 8. The method of claim 7, wherein the preservative is lessthan 0.005 wt. %.
 9. The method of claim 7, wherein the preservative isbenzalkonium chloride.